Sumitomo Mitsui DS Asset Management Company Ltd Buys 344 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.9% during the fourth quarter, Holdings Channel reports. The fund owned 18,859 shares of the medical equipment provider’s stock after acquiring an additional 344 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Zimmer Biomet were worth $2,295,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ZBH. Vontobel Holding Ltd. grew its holdings in Zimmer Biomet by 4.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 8,540 shares of the medical equipment provider’s stock worth $958,000 after acquiring an additional 366 shares during the last quarter. IFP Advisors Inc grew its holdings in Zimmer Biomet by 20.4% during the 3rd quarter. IFP Advisors Inc now owns 2,763 shares of the medical equipment provider’s stock worth $310,000 after acquiring an additional 469 shares during the last quarter. PFG Advisors grew its holdings in Zimmer Biomet by 7.5% during the 3rd quarter. PFG Advisors now owns 1,815 shares of the medical equipment provider’s stock worth $204,000 after acquiring an additional 126 shares during the last quarter. Ziegler Capital Management LLC grew its holdings in Zimmer Biomet by 10.2% during the 3rd quarter. Ziegler Capital Management LLC now owns 30,915 shares of the medical equipment provider’s stock worth $3,469,000 after acquiring an additional 2,852 shares during the last quarter. Finally, Impact Partnership Wealth LLC bought a new stake in Zimmer Biomet during the 3rd quarter worth about $52,000. Institutional investors own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ZBH shares. Citigroup upped their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Evercore ISI upped their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Barclays upped their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. TheStreet upgraded shares of Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $130.00 target price on shares of Zimmer Biomet in a research report on Friday, February 23rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and an average price target of $139.39.

Insider Buying and Selling

In other news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Price Performance

NYSE ZBH opened at $121.52 on Wednesday. The business has a 50 day simple moving average of $126.19 and a 200 day simple moving average of $119.44. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $149.25. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The stock has a market cap of $24.97 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 2.22 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The business had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.93 billion. During the same period in the prior year, the business earned $1.88 EPS. Zimmer Biomet’s revenue for the quarter was up 6.3% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a dividend of $0.24 per share. The ex-dividend date is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.79%. Zimmer Biomet’s payout ratio is 19.63%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.